Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 3,580 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: patch Clear all

Conditions: Head and Neck Cancer
Interventions: metal patch tests; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Genetic Disorder, Asperger Disorder, Autism Spectrum Disorder, Fragile X Syndrome, Developmental Delay
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 1 Year to 99 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatocellular Carcinoma
Interventions: RFA Physics Library -- a Planning and Guidance Platform (PGP); Device
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Low or Intermediate Risk Prostate Cancer
Interventions: MR guided Linear Accelerator; Radiation
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Adult Medulloblastoma, Childhood Medulloblastoma, Neuroblastoma, Neuroendocrine Tumor, Somatostatinoma
Interventions: gallium Ga 68-edotreotide, positron emission tomography/computed tomography, indium In 111 pentetreotide, computed tomography, contrast-enhanced magnetic resonance imaging; Drug · Procedure · Radiation
Lead sponsor: Sue O'Dorisio; Other
Eligibility: 2 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Smoking Cessation, Tobacco Use Disorder
Interventions: nicotine transdermal system; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2005
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Non Small Cell Lung Cancer, Lung Cancer
Interventions: FLT3 Ligand (CDX-301), anti-CD40 antibody (CDX-1140), SBRT; Drug · Biological · Radiation
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Coronary Artery Disease
Interventions: Percutaneous Coronary Intervention; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 34
States / cities: Little Rock, Arkansas • Glendale, California • Hartford, Connecticut + 30 more

Conditions: Smoking Cessation
Interventions: Nicotine Replacement Therapy (NRT), Questionnaire, Counseling, Self-Help Materials; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Lorlatinib; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV
Interventions: Personal Approaches to Treatment Choices for HIV, Stress Reduction Skills Program; Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 21 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Herpes
Interventions: Not listed
Lead sponsor: Luminex Corporation; Industry
Eligibility: Not listed
Enrollment: 1,963 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 3
States / cities: Springfield, Massachusetts • Albuquerque, New Mexico • Burlington, North Carolina

Conditions: Verruca, Warts
Interventions: Veregen only, Cryotherapy and Veregen; Drug · Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 6 Years to 16 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Fibrodysplasia Ossificans Progressiva
Interventions: Andecaliximab, Placebo; Drug
Lead sponsor: Ashibio Inc; Industry
Eligibility: 2 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania

Conditions: Coronary Artery Disease
Interventions: ABT NG DES 48 EECSS; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 18
States / cities: Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 13 more

Conditions: Smoking Cessation
Interventions: Treatment As Usual (TAU), Nicotine Replacement Therapies, Text Message Intervention (TMI); Other · Drug · Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Geographic Atrophy, Age-related Macular Degeneration
Interventions: LFG316, Sham, LFG316 Lower dose; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 55 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 19
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 15 more

Conditions: Prostate Cancer
Interventions: Artemis™ software system; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 40 Years to 85 Years · Male only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Plantar Warts
Interventions: Nowarta110, Placebo; Drug
Lead sponsor: Nowarta Biopharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Huntington Beach, California

Conditions: Keratosis, Actinic
Interventions: Swift System; Device
Lead sponsor: Blackwell Device Consulting; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Anxiety, Sleep
Interventions: Active dermal patch, Placebo patch; Device
Lead sponsor: Natural Immune Systems Inc; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Klamath Falls, Oregon

Conditions: Peripheral Arterial Disease
Interventions: DETOUR System; Device
Lead sponsor: Endologix; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 30
States / cities: Scottsdale, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 27 more

Conditions: Breast Cancer
Interventions: 89Zr-Trastuzumab Human Dosimetry and Safety, HER2 Positive Lesion Detection and Safety; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Meningioma, Glioblastoma, Acoustic Neuroma, Brain Cancer, Pituitary Adenoma
Interventions: Panitumumab-IRDye800; Drug
Lead sponsor: Eben Rosenthal; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Contact Allergies to Dental Metal as a Possible Risk Factor for Oral Cancer

Pediatric Patients With Metabolic or Other Genetic Disorders

An Intraoperative Guidance Platform for Radio Frequency Ablation

Phase I Study MR-guided SBRT to PCa

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

Effectiveness of the Nicotine Patch in Suppressing Nicotine Withdrawal Symptoms in Women Versus Men - 1

FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy

Multi-center Prospective Study to Evaluate Outcomes of the Moderate to Severely Calcified Coronary Lesions (MACE)

Determinants of Smoking Cessation Among Latinos

A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions

Increasing Motivation for Antiretroviral Therapy Initiation: A Pilot Intervention

A Two Arm, Multi-Site Clinical Evaluation of the ARIES HSV 1&2 Assay in Symptomatic Patients

Investigating Veregen ™ 15% Ointment Treatment For Non-facial Verrucae in Pediatric Patients: A Pilot Study

A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

Abbott Next Generation Drug Eluting Stent 48mm Study

A Pilot Text Messaging Intervention to Reduce Smoking in Office-based Buprenorphine and Inpatient Detoxification Patients

Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)

Comparative Analysis of Transperineal Versus Transrectal Approaches for MRI-Targeted Biopsy of the Prostate for the Detection and Characterization of Prostate Cancer

A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts

Microwave Treatment for Actinic Keratosis

Longterm Effects of a Biofield Patch on Anxiety, Sleep, and Energy

The DETOUR 2 Clinical Trial

89ZrTrastuzumab Breast Imaging With Positron Emission Tomography

Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures